Carmustine and Hair loss - a phase IV clinical study of FDA data

Summary:

Hair loss is reported as a side effect among people who take Carmustine (carmustine), especially for people who are female, 50-59 old, also take Taxotere, and have Breast cancer female.

The phase IV clinical study analyzes which people have Hair loss when taking Carmustine. It is created by eHealthMe based on reports of 4,562 people who have side effects when taking Carmustine from the FDA, and is updated regularly.

What is Carmustine?

Carmustine has active ingredients of carmustine. eHealthMe is studying from 4,562 Carmustine users. Check the latest studies of Carmustine.

What is Hair loss?

Hair loss is found to be associated with 2,412 drugs and 3,513 conditions by eHealthMe. Check the latest studies of Hair loss.

On Jul, 11, 2026

4,562 people reported to have side effects when taking Carmustine.
Among them, 18 people (0.39%) have Hair loss.

Among these 18 people:

What is the gender of people who have Hair loss when taking Carmustine? *

female: 100 %
male: 0.0 %

What is the age of people who have Hair loss when taking Carmustine? *

What are other drugs people take besides Carmustine? *

What are other side effects people have besides Hair loss? *

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 8 people, 44.44%
Psychological Trauma: 7 people, 38.89%
Vision Blurred: 6 people, 33.33%
Dyspnea (difficult or laboured breathing): 6 people, 33.33%
Rashes (redness): 5 people, 27.78%
Fatigue (feeling of tiredness): 5 people, 27.78%
Nausea (feeling of having an urge to vomit): 5 people, 27.78%
Cough: 4 people, 22.22%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 4 people, 22.22%
Multiple Myeloma (cancer of the plasma cells): 4 people, 22.22%

What are the existing conditions these people have? *

Breast Cancer Female: 7 people, 38.89%
Multiple Myeloma (cancer of the plasma cells): 4 people, 22.22%
Hodgkin's Lymphoma (cancer originating from white blood cells): 2 people, 11.11%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 5.56%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 5.56%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 5.56%
Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 1 person, 5.56%
Breast Cancer: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Carmustine and have Hair loss?

- Check whether Hair loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carmustine:

Carmustine (4,562 reports)

Hair loss treatments and more:

Hair loss (271,201 reports)

Browse all side effects of Carmustine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hair loss:

Hair loss (2,412 drugs)

Browse all the conditions that are associated with Hair loss:

Hair loss (3,513 conditions)

Related publications that referenced our studies

Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .
Lindsey SF, Tosti A, "Hair loss induced by tumor necrosis factor alpha inhibitors", J Clin Investigat Dermatol, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carmustine (the active ingredients of Carmustine) and Carmustine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.